Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Sohini Mondal

UNBELIEVABLE: Is incyte stock underperforming the nasdaq - The Untold Story

With a market cap of $14.2 billion, Wilmington, Delaware-based Incyte Corporation (INCY) is a biopharmaceutical company specializing in developing therapies for oncology, hematology, and autoimmune diseases. The company's key products include Jakafi for myelofibrosis and polycythemia vera, along with a diverse pipeline of innovative treatments.

Companies valued at $10 billion or more are generally labeled as “large-cap” stocks, and Incyte fits this criterion perfectly. Incyte's uniqueness lies in its specialization in developing breakthrough JAK inhibitors and groundbreaking small-molecule drugs, setting it apart as a leader in precision medicine.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.